Sanuwave Health Selected for Inclusion in Russell 2000® Index

Rhea-AI Summary

Sanuwave Health (NASDAQ: SNWV), a provider of non-invasive wound care solutions, has been selected for inclusion in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30. The company will also be included in the broader Russell 3000® Index and Russell Microcap® Index.

The Russell indexes, which capture the 4,000 largest U.S. stocks by market capitalization, are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked to these indexes as of June 2024. Membership in these indexes remains in place for one year.

Sanuwave Health specializes in regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions through their patented energy transfer technologies.

Positive

• Inclusion in Russell 2000® Index increases visibility to institutional investors
• Access to broader investor base through inclusion in multiple Russell indexes
• Potential for increased trading volume and liquidity due to index fund investments
• Association with indexes tracking $10.6 trillion in benchmarked assets

Negative

• None.

Insights

Investment Index Analyst

Sanuwave's inclusion in Russell 2000 Index increases visibility to institutional investors, potentially improving trading liquidity and passive fund inflows.

Sanuwave Health's inclusion in the Russell 2000® Index represents a significant milestone for the company's market visibility. The Russell indexes are not merely symbolic designations - they're powerful investment vehicles that directly influence capital flows. With approximately $10.6 trillion in assets benchmarked to Russell U.S. indexes as of June 2024, this inclusion automatically exposes Sanuwave to a substantial pool of institutional capital.

The mechanics of this inclusion are particularly favorable. Sanuwave will join not only the Russell 2000® (small-cap companies) but also the broader Russell 3000® Index and the Russell Microcap® Index. This triple inclusion creates multiple channels for passive investment inflows, as index funds tracking these benchmarks will need to purchase Sanuwave shares to maintain proper tracking.

The timing of the reconstitution (effective June 30) gives the market a month to anticipate these mandatory purchases, potentially creating pre-inclusion price action. More importantly, the long-term benefits extend beyond temporary price movements. The increased liquidity typically reduces bid-ask spreads, making the stock more attractive to institutional investors who require sufficient trading volume. The increased analyst coverage that often follows Russell inclusion can further enhance market awareness of Sanuwave's wound care portfolio and regenerative medicine technologies.

The significance of this development should be viewed in context of Sanuwave's medical technology focus - an area where institutional backing can provide both capital resources and validation in a highly competitive healthcare landscape.

EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company’s inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® Index.

The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, results in automatic inclusion in either the Russell 1000® Index or the Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines index membership primarily by objective, market-capitalization rankings and style attributes.

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 2024, approximately $10.6 trillion in assets were benchmarked to the Russell U.S. indexes, which are maintained by FTSE Russell, a leading global index provider.

For more information about the Russell indexes and the annual reconstitution process, please visit the “Russell Reconstitution” section on the FTSE Russell website.

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact: investors@sanuwave.com

FAQ

When will Sanuwave Health (SNWV) be added to the Russell 2000 Index?

Sanuwave Health will be added to the Russell 2000 Index effective June 30, 2025, after the U.S. market opens.

Which Russell indexes will SNWV be included in for 2025?

SNWV will be included in the Russell 2000® Index, Russell 3000® Index, and Russell Microcap® Index.

How long will Sanuwave Health remain in the Russell indexes?

Membership in the Russell indexes remains in place for one year following the annual reconstitution.

What is Sanuwave Health's main business focus?

Sanuwave Health focuses on non-invasive wound care solutions and regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

How much in assets are benchmarked to the Russell U.S. indexes?

Approximately $10.6 trillion in assets were benchmarked to the Russell U.S. indexes as of June 2024.